1Moller J,Nielsen GM,Tvedegaard KC,et al.A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scandinavian Journal of Clinical and Laboratory Investigation . 2000
2Stuhlinger MC,Tsao PS,Her JH,et al.Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation . 2001
3Homocysteine Studies Collaboration.Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. Journal of the American Medical Association, The . 2002
4Mattson MP,Shea TB.Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends in Neurosciences . 2003
5Valkonen VP,Pavia H,Salonen JT,et al.Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet,The . 2001
6Perry IJ,Refsum H,Morris RW,et al.Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. The Lancet . 1995
7Yoo J H,Chor G D,Kang S S.Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia. Arteriosclerosis and Thrombosis . 2000
8Boysen G,Brander T,Christensen H,et al.Homocysteine and risk of recurrent stroke. Stroke . 2003
9Wanby P,Teerlink T,Brudin L, et al.Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis . 2006
10Saposnik G,Ray JG,Sheridan P,et al.Homocysteine-lowering therapy and stroke risk,severity,and disability:additional findings from the HOPE 2 trial. Stroke . 2009
